Follow-up of patients with early breast cancer: Is it time to rewrite the story?

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 2, 2014, Pages 130-141

  Puglisi, Fabio ^a,b   Fontanella, Caterina ^a   Numico, Gianmauro ^c   Sini, Valentina ^d   Evangelista, Laura ^e   Monetti, Francesco ^f   Gori, Stefania ^g   Del Mastro, Lucia ^f  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c Aosta Hospital   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g Centre for Tropical Diseases   (Italy)

Author keywords

Early breast cancer; Follow up; Surveillance; Survivorship care

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MICRORNA; PROTEIN P53;

ANXIETY; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; BREAST CANCER; BREAST SELF EXAMINATION; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CIRCULATING TUMOR CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; EARLY CANCER; ECHOGRAPHY; FOLLOW UP; GENE MUTATION; HEALTH CARE MANAGEMENT; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAMMOGRAPHY; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIC EXAMINATION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REASSURANCE; REVIEW; SURVIVOR; X RAY; BREAST; BREAST NEOPLASMS; FEMALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

BREAST; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 84903478998     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.03.001     Document Type: Review

References (126)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Burstein H.J., Winer E.P. Primary care for survivors of breast cancer. N Engl J Med 2000, 343(15):1086-1094.
3. Rojas M.P., Telaro E., Moschetti I., et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2009, 25(1):CD001768. [review].
4. Koch L., Jansen L., Herrmann A., et al. Quality of life in long-term breast cancer survivors - a 10-year longitudinal population-based study. Acta Oncol 2013, 52(6):1119-1128.
5. Jacobs H.J., van Dijck J.A., de Kleijn E.M., Kiemeney L.A., Verbeek A.L. Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol 2001, 12(8):1107-1113.
6. The GIVIO Investigators Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994, 271(20):1587-1592.
7. Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial, National Research Council Project on Breast Cancer follow-up. JAMA 1994, 271((20) May):1593-1597.
8. Palli D., Russo A., Saieva C., et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA 1999, 281(17):1586.
9. Gulliford T., Opomu M., Wilson E., Hanham I., Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ 1997, 314(7075):174-177.
10. Grunfeld E., Mant D., Yudkin P., et al. Routine follow up of breast cancer in primary care: randomized trial. BMJ 1996, 313(7058):665-669.
11. Grunfeld E., Levine M.N., Julian J.A., et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006, 24(6):848-855.
12. Khatcheressian J.L., Hurley P., Bantug E., et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(7):961-965.
13. Hayes D.F. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 2007, 356(24):2505-2513.
14. NCCN Guidelines: Breast Cancer Version 3. ; 2013; [accessed 27.01.14]. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
15. Aebi S., Davidson T., Gruber G., Cardoso F. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl. 6):vi12-vi24.
16. Mille D., Roy T., Carrère M.O., et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol 2000, 18(8):1718-1724.
17. Potosky A.L., Han P.K., Rowland J., et al. Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med 2011, 26(12):1403-1410.
18. Schnipper L.E., Smith T.J., Raghavan D., et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012, 30(14):1715-1724.
19. Grunfeld E., Hodgson D.C., Del Giudice M.E., Moineddin R. Population-based longitudinal study of follow-up care for breast cancer survivors. J Oncol Pract 2010, 6(4):174-181.
20. Keating N.L., Landrum M.B., Guadagnoli E., Winer E.P., Ayanian J.Z. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007, 25(9):1074-1081.
21. Numico G., Pinto C., Ucci G., et al. How are cared surviving cancer patients? Results of an Italian national survey to medical oncologists (MO) about clinical and organizational features of follow-up (FU). J Clin Oncol (Proc ASCO Annu Meet) 2012, 30(15 Suppl.):e19592.
22. Mayer E.L., Gropper A.B., Neville B.A., et al. Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol 2012, 30(2):158-163.
23. Earle C.C. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol 2006, 24(32):5112-5116.
24. Grunfeld E., Moineddin R., Gunraj N., et al. Cancer screening practices of cancer survivors: population-based, longitudinal study. Can Fam Physician 2012, 58(9):980-986.
25. Jatoi I., Anderson W.F., Jeong J.H., Redmond C.K. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011, 29((17) June):2301-2304. [erratum in: J Clin Oncol 2010;29(29);3948].
26. Guiu S., Michiels S., André F., et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012, 23(12):2997-3006.
27. Cianfrocca M., Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin 2009, 59(5):303-313.
28. Goldhirsch A., Winer E.P., Coates A.S., et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-2223.
29. Metzger-Filho O., Sun Z., Viale G., et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013, 31((25) September):3083-3090.
30. Jatoi I., Anderson W.F., Jeong J.H., Redmond C.K. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011, 29(17):2301-2304.
31. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER cancer statistics review, 1975-2001 2004, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2001/.
32. Waeber M., Castiglione-Gertsch M., Dietrich D., et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003, 14((8) August):1215-1221.
33. Aebi S., Gelber S., Lang I., et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (chemotherapy as adjuvant for locally recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Cancer Res 2012, 72(24 Suppl.):96s. [abstract S3-2].
34. Elder E.E., Kennedy C.W., Gluch L., et al. Patterns of breast cancer relapse. Eur J Surg Oncol 2006, 32(9):922-927.
35. Saigal K., Hurley J., Takita C., et al. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. Clin Breast Cancer 2013, 13(5):335-343.
36. Yadav B.S., Sharma S.C., Singh R., Singh G. Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther 2007, 3((2) April-June):75-80.
37. Lu W.L., Jansen L., Post W.J., Bonnema J., Van de Velde J.C., De Bock G.H. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009, 114(3):403-412.
38. Stomper P.C., Winston J.S., Herman S., Klippenstein D.L., Arredondo M.A., Blumenson L.E. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 1997, 45(1):39-46.
39. Dershaw D.D., McCormick B., Osborne M.P. Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 1992, 70(2):493-496.
40. Orel S.G., Troupin R.H., Patterson E.A., Fowble B.L. Breast cancer recurrence after lumpectomy and irradiation: role of mammography in detection. Radiology 1992, 183(1):201-206.
41. Winehouse J., Douek M., Holz K., et al. Contrast-enhanced colour Doppler ultrasonography in suspected breast cancer recurrence. Br J Surg 1999, 86(9):1198-1201.
42. Hagay C., Cherel P.J., de Maulmont C.E., et al. Contrast-enhanced CT: value for diagnosing local breast cancer recurrence after conservative treatment. Radiology 1996, 200(3):631-638.
43. Belli P., Costantini M., Romani M., Marano P., Pastore G. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002, 73(3):223-235.
44. Orel S.G., Schnall M.D. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001, 220(1):13-30.
45. Pan L., Han Y., Sun X., Liu J., Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010, 136(7):1007-1022.
46. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437.
47. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
48. Lehman C.D., Blume J.D., Weatherall P., et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005, 103(9):1898-1905.
49. Menell J.H., Morris E.A., Dershaw D.D., Abramson A.F., Brogi E., Liberman L. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005, 11(6):382-390.
50. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317-1325.
51. Houssami N., Hayes D.F. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer?. CA Cancer J Clin 2009, 59(5):290-302.
52. Mumtaz H., Davidson T., Hall-Craggs M.A., et al. Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. Br J Surg 1997, 84((8) August):1147-1151.
53. Friedrich M. MRI of the breast: state of the art. Eur Radiol 1998, 8(5):707-725.
54. Krämer S., Schulz-Wendtland R., Hagedorn K., Bautz W., Lang N. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res 1998, 18(3 C):2159-2161.
55. Rieber A., Merkle E., Zeitler H., et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997, 21(5):780-784.
56. Gilles R., Guinebretière J.M., Shapeero L.G., et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993, 188(2):473-478.
57. Dao T.H., Rahmouni A., Campana F., Laurent M., Asselain B., Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993, 187(3):751-755.
58. Hathaway P.B., Mankoff D.A., Maravilla K.R., et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999, 210(3):807-814.
59. Panageas K.S., Sima C.S., Liberman L., Schrag D. Use of high technology imaging for surveillance of early stage breast cancer. Breast Cancer Res Treat 2012, 131(2):663-670.
60. Houssami N., Turner R., Macaskill P., et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014, 32(5):392-401.
61. Hortobagyi G.N. Can we cure limited metastatic breast cancer?. J Clin Oncol 2002, 20(3):620-623.
62. Kobayashi T., Ichiba T., Sakuyama T., et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012, 19(3):218-237.
63. Tomiak E., Piccart M., Mignolet F., et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer 1996, 32A(11):1876-1887.
64. Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14(8):2197-2205.
65. Singletary S.E., Walsh G., Vauthey J.N., et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003, 8(3):241-251.
66. Girard P., Baldeyrou P., Le Chevalier T., et al. Surgery for pulmonary metastases. Who are the 10-year survivors?. Cancer 1994, 74((10) November):2791-2797. PubMed PMID: 7954238.
67. McKenna R.J., McMurtrey M.J., Larson D.L., Mountain C.F. A perspective on chest wall resection in patients with breast cancer. Ann Thorac Surg 1984, 38(5):482-487.
68. Temple W.J., Ketcham A.S. Surgical management of isolated systemic metastases. Semin Oncol 1980, 7(4):468-480.
69. Holmes F.A., Buzdar A.U., Kau S-W., et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): The M.D. Anderson experience. Breast Dis 1994, 7:7-20.
70. Berman A.T., Thukral A.D., Hwang W.T., Solin L.J., Vapiwala N. Incidence patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer 2013, 13:88-94.
71. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
72. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28(1):92-98.
73. Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366(2):109-119.
74. Swain S.M., Kim S.B., Cortés J., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(6):461-471.
75. Pennant M., Takwoingi Y., Pennant L., et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010, 14(50):1-103.
76. Radan L., Ben-Haim S., Bar-Shalom R., Guralnik L., Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006, 107(11):2545-2551.
77. Ternier F., Houvenaeghel G., Lecrivain F., et al. Computed tomography in suspected local breast cancer recurrence. Breast Cancer Res Treat 2006, 100(3):247-254.
78. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003, 38(5):250-256.
79. Piperkova E., Raphael B., Altinyay M.E., et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 2007, 32(6):429-434.
80. Hamaoka T., Madewell J.E., Podoloff D.A., Hortobagyi G.N., Ueno N.T. Bone imaging in metastatic breast cancer. J Clin Oncol 2004, 22(14):2942-2953.
81. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998, 16(6):2038-2044.
82. Rubens R.D. Bone metastases-the clinical problem. Eur J Cancer 1998, 34(2):210-213.
83. Matro J.M., Goldstein L.J. How do I follow patients with early breast cancer after completing adjuvant therapy. Curr Treat Options Oncol 2013, 15(1):63-78.
84. Muindi J., Coombes R.C., Golding S., Powles T.J., Khan O., Husband J. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983, 56(664):233-236.
85. Kamholtz R., Sze G. Current imaging in spinal metastatic disease. Semin Oncol 1991, 18(2):158-169.
86. Houssami N., Costelloe C.M. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol 2012, 23(4):834-843.
87. Yeh K.A., Fortunato L., Ridge J.A., Hoffman J.P., Eisenberg B.L., Sigurdson E.R. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol 1995, 2(4):319-324.
88. Liu T., Cheng T., Xu W., Yan W.L., Liu J., Yang H.L. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 2011, 40:523-531.
89. Siggelkow W., Zimny M., Faridi A., Petzold K., Buell U., Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003, 23(2C):1859-1867.
90. Peterson J.J., Kransdorf M.J., O'Connor M.I. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003, (415 Suppl.):S120-S128.
91. Evangelista L., Baretta Z., Vinante L., et al. Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer. Ann Nucl Med 2011, 25:469-477.
92. Evangelista L., Cervino A.R., Ghiotto C., Al-Nahhas A., Rubello D., Muzzio P.C. Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clin Nucl Med 2012, 37:467-474.
93. Parmar A.D., Sheffield K.M., Vargas G.M., Han Y., Chao C., Riall T.S. Quality of post-treatment surveillance of early stage breast cancer in Texas. Surgery 2013, 154:214-225.
94. Constantinidou A., Martin A., Sharma B., Johnston S.R. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011, 22:307-314.
95. Dose J., Bleckmann C., Bachmann S., et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002, 23(9):857-864.
96. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003, 38:250-256.
97. Siggelkow W., Zimny M., Faridi A., Petzold K., Buell U., Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003, 23:1859-1867.
98. Eubank W.B., Mankoff D., Bhattacharya M., et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004, 183:479-486.
99. Santiago J.F., Gonen M., Yeung H., Macapinlac H., Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006, 50:61-67.
100. Liu C.S., Shen Y.Y., Lin C.C., Yen R.F., Kao C.H. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002, 32(7):244-247.
101. Groheux D., Giacchetti S., Moretti J.L., et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011, 38(3):426-435.
102. Isasi C.R., Moadel R.M., Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005, 90(2):105-112.
103. Abe K., Sasaki M., Kuwabara Y., et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005, 19(7):573-579.
104. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001, 22(8):875-879.
105. Dirisamer A., Halpern B.S., Flöry D., et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010, 73(2):294-299.
106. Haug A.R., Schmidt G.P., Klingenstein A., et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007, 31(4):629-634.
107. Vranjesevic D., Filmont J.E., Meta J., et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002, 43(3):325-329.
108. Wolfort R.M., Li B.D., Johnson L.W., et al. The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg 2006, 30(8):1422-1427.
109. Buck A.K., Herrmann K., Stargardt T., Dechow T., Krause B.J., Schreyögg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Technol 2010, 38(1):6-17.
110. Huang B., Law M.W., Khong P.L. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009, 251(1):166-174.
111. Ghotbi N., Iwanaga M., Ohtsuru A., Ogawa Y., Yamashita S. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Asian Pac J Cancer Prev 2007, 8(1):93-97.
112. Bates S.E. Clinical applications of serum tumor markers. Adv Intern Med 1991, 115(8):623-638.
113. Narod S.A. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010, 7(12):702-707.
114. Yamamoto M., Hosoda M., Nakano K., et al. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci. 2013, [Epub ahead of print]. 10.1111/cas.12302.
115. Stathopoulou A., Vlachonikolis I., Mavroudis D., et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002, 20(16):3404-3412.
116. Saloustros E., Perraki M., Apostolaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res 2011, 13(3):R60.
117. Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009, 117(3):483-495.
118. Carlson J.J., Roth J.A. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013, 141(1):13-22.
119. Dowsett M., Sestak I., Lopez-Knowles E., et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013, 31(22):2783-2790.
120. Varga Z., Sinn P., Fritzsche F., et al. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS ONE 2013, 8(3):e58483.
121. Naoi Y., Kishi K., Tsunashima R., et al. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients. Breast Cancer Res Treat 2013, 140(2):299-306.
122. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
123. Corcoran C., Friel A.M., Duffy M.J., Crown J., O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011, 57:18-32.
124. Markou A., Yousef G.M., Stathopoulos E., Georgoulias V., Lianidou E. Prognostic significance of metastasis-related MicroRNAs in early breast cancer patients with a long follow-up. Clin Chem 2014, 60(1):197-205.
125. Cuk K., Zucknick M., Madhavan D., et al. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS ONE 2013, 8(10):e76729.
126. Linee guida AIOM -Associazione Italiana di Oncologia Medica- http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida/1,333,1.